Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM3XNUI)

• Drug Name: Tazobactam Drug Info
• Synonyms: TAZ; CL298741; YTR830H; CL-298741; Piprataz (TN); YTR-830H; Tazobactam (JAN/USAN/INN); (2S,3S,5R)-3-methyl-4,4,7-trioxo-3-(triazol-1-ylmethyl)-4; (2S,3S,5R)-3-methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide
• Therapeutic Class: Antiinfective Agents
• Cross-matching ID:
  PubChem CID: 123630
  ChEBI ID: CHEMBL404
  CAS Number: CAS 89786-04-9
  TTD Drug ID: D0QQ7D
  INTEDE Drug ID: DR2453

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Fluid shear stress and atherosclerosis	-1.69	3.53e-2	123/139 (88.49%)	IKBKB;GSTM2;IL1B;...
Autoimmune thyroid disease	-1.69	3.69e-2	46/53 (86.79%)	CD80;CD28;CD40LG;...
Bladder cancer	-1.69	3.95e-2	40/41 (97.56%)	MMP9;E2F2;FGFR3;...
Ferroptosis	-1.70	3.93e-2	36/41 (87.8%)	ATG5;FTL;TFRC;...
Oxidative phosphorylation	-1.70	4.08e-2	93/133 (69.92%)	COX6C;NDUFAB1;NDUFB7;...
IL-17 signaling pathway	-1.71	3.77e-2	84/94 (89.36%)	IL6;CSF3;CCL7;...
Collecting duct acid secretion	-1.71	3.83e-2	22/27 (81.48%)	ATP6V0C;ATP6V0E1;ATP6V1D;...
Cholesterol metabolism	-1.73	4.02e-2	44/50 (88%)	SOAT1;APOA2;APOE;...
Kaposi sarcoma-associated herpesvirus infection	-1.75	3.99e-2	172/193 (89.12%)	IFNAR1;IKBKB;TCF7;...
Tyrosine metabolism	-1.77	3.35e-2	30/36 (83.33%)	FAH;ADH6;MAOB;...
Glutathione metabolism	-1.80	2.13e-2	43/57 (75.44%)	PRDX6;GSTM1;ANPEP;...
Type I diabetes mellitus	-1.83	1.70e-2	38/43 (88.37%)	LTA;IL12B;CD80;...
Graft-versus-host disease	-1.84	2.13e-2	32/42 (76.19%)	CD80;CD28;HLA-DOB;...
Metabolism of xenobiotics by cytochrome P450	-1.92	1.42e-2	49/77 (63.64%)	CYP2A13;GSTM2;ALDH3B1;...
Rheumatoid arthritis	-1.93	1.60e-2	78/93 (83.87%)	FLT1;ATP6V1E1;CD28;...
Mineral absorption	-2.07	1.06e-2	48/60 (80%)	FXYD2;ATOX1;SLC31A1;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	0.01uM - 10uM	6H, 24H	Hide ▲

Cervix

Cervical adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HeLa	CVCL_0030	Homo sapiens	0.01uM - 10uM	3H, 24H	Hide ▲

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Normal (Transformed)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HEK293	CVCL_0045	Homo sapiens	0.04uM - 10uM	24H	Show ▼

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Pancreas

Pancreatic carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
YAPC	CVCL_1791	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.01uM - 10uM	24H	Show ▼